未登录

M

Michal Stark

technion israel institute of technology

H指数:18

被引数:1,357

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response

靶向溶酶体以增强抗癌治疗和免疫应答

International Journal of Biological Sciences

IF10

2026-01-010

PRE

Doubly Stimulated Corrole for Organelle-Selective AntitumorCytotoxicity

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-04-1812

PRE

Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

解读复发性AML患者化疗耐药的分子机制: 迈向克服耐药性的精准医学

CANCER CELL INTERNATIONAL

IF6

2021-01-1430

OAAI

The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane

IF5.2

2020-04-2739

OAAI

Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine

CELL DEATH & DISEASE

IF9.6

2019-05-1737

OAAI

Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity

CELL DEATH & DISEASE

IF9.6

2018-12-1396

OAAI

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

ANNALS OF ONCOLOGY

IF65.4

2017-11-0137

OAAI

Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer

叶酸聚 γ-谷氨酸合成酶: 癌症中叶酸稳态和抗叶酸耐药性的关键决定因素

DRUG RESISTANCE UPDATES

IF21.7

2016-09-0172

PREAI

Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2015-11-2541

OA

Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed

CANCER RESEARCH

IF16.6

2015-08-011

PRE

Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest

CELL DEATH & DISEASE

IF9.6

2014-02-2062

OAAI

Alterations in FPGS splicing as a plausible underlying mechanism of MTX resistance in ALL.

CANCER RESEARCH

IF16.6

2013-04-010

PRE

Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers

CELL DEATH & DISEASE

IF9.6

2012-04-0587

OAAI

Heterogeneous Nuclear Ribonucleoprotein H1/H2-dependent Unsplicing of Thymidine Phosphorylase Results in Anticancer Drug Resistance

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2011-02-0146

OAAI

Arabinogalactan-Folic Acid-Drug Conjugate for Targeted Delivery and Target-Activated Release of Anticancer Drugs to Folate Receptor-Overexpressing Cells

BIOMACROMOLECULES

IF5.4

2009-12-16127

PRE

Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance

IF7.7

2009-12-01126

OAAI

The reduced folate carrier gene is a novel selectable marker for recombinant protein overexpression

MOLECULAR PHARMACOLOGY

IF3

2005-09-0117

PREAI

Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene

MOLECULAR PHARMACOLOGY

IF3

2004-12-0119

PREAI

Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2004-05-2617

OAAI

Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2004-01-0147

OAAI